Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TLX | 6-K | bullish | 8/10 | Telix Pharmaceuticals announced FDA approval of Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging dr | Sep 14, 2026 |
| LGND | CLUSTER | neutral | 3/10 | Two insiders at Ligand Pharmaceuticals sold a combined $427K in open-market transactions over a one-week window. The sal | Sep 14, 2026 |
| INBX | 144 | neutral | 2/10 | Director Kimberly Manhard filed a Form 144 notice to sell 500 shares of Inhibrx Biosciences common stock, with an approx | Sep 14, 2026 |
| HYFT | 6-K | bearish | 7/10 | MindWalk reported FQ1 2027 revenue of $3.8M (+21% YoY) and gross margin expansion to 59% from 48%, driven by the commerc | Sep 14, 2026 |
| SAFX | DEFA14A, 425 | bearish | 7/10 | XCF Global (SAFX) filed Amendment No. 1 to its Business Combination Agreement with DevvStream and Southern Energy, along | Sep 14, 2026 |
| ZSQR | 8-K | mixed | 6/10 | Z Squared Inc. closed its acquisition of Paradox Data LLC, issuing 5,000 shares of Series A Convertible Preferred Stock | Sep 14, 2026 |
| AIM | 8-K | bearish | 7/10 | AIM ImmunoTech converted approximately $400,000 of its existing promissory note with Streeterville Capital into 1,749,43 | Sep 14, 2026 |
| BNTC | PRESS-RELEASE | neutral | 5/10 | Benitec Biopharma reported fiscal year 2026 results with a net loss of $45.5M ($0.98/share) vs $37.9M ($1.05/share) in F | Sep 14, 2026 |
| SAFX | 8-K | bullish | 7/10 | XCF Global entered Amendment No. 1 to its Business Combination Agreement with DevvStream and Southern Energy, which dele | Sep 14, 2026 |
| AGMB | PRESS-RELEASE | bullish | 6/10 | Agomab Therapeutics announced positive Phase 1 results for AGMB-447, a candidate for idiopathic pulmonary fibrosis (IPF) | Sep 14, 2026 |
| NYMXF | 20-F | bearish | 8/10 | Nymox Pharmaceutical's FY2025 20-F reveals a pre-revenue biopharma with a going-concern qualification, only $6,000 cash, | Sep 14, 2026 |
| PHVS | CLUSTER | neutral | 3/10 | Pharvaris N.V. (PHVS), insider cluster of 3 sells totaling $2.06M over the last 7 days, led by Chief Early Development o | Sep 14, 2026 |
| ALLR | 8-K | neutral | 2/10 | Allarity Therapeutics filed an 8-K with Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), but | Sep 14, 2026 |
| ONCO | 8-K | bearish | 6/10 | Onconetix (ONCO) entered into a Grid Promissory Note to lend Realbotix LLC up to $5.0 million, with an initial $2.5 mill | Sep 14, 2026 |
| ONCO | DEFA14A, 8-K | neutral | 4/10 | Onconetix (ONCO) entered into a Grid Promissory Note to lend Realbotix LLC up to $5.0 million, with an initial $2.5 mill | Sep 14, 2026 |
| AUTL | S-3 | neutral | 4/10 | Autolus Therapeutics filed an S-3 registration statement to register 3,500,000 ADSs for resale by Perceptive Credit Hold | Sep 14, 2026 |
| NRXP | 8-K | neutral | 2/10 | NRX Pharmaceuticals filed an 8-K furnishing an investor presentation used in meetings with investors and analysts on Sep | Sep 14, 2026 |
| LEGN | 6-K | neutral | 3/10 | Legend Biotech filed a 6-K on September 14, 2026, making an updated clinical pipeline available on its website. The pipe | Sep 14, 2026 |
| TELO | 8-K | neutral | 4/10 | Telomir Pharmaceuticals announced preclinical in-vitro data from Ohio State University showing Telomir-Zn inhibits cell | Sep 14, 2026 |
| SRRK | 8-K | bullish | 8/10 | Scholar Rock announced FDA approval of ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy (SMA) in patients aged 2+ | Sep 14, 2026 |
| CABA | 8-K | neutral | 4/10 | Cabaletta Bio reports that warrants issued in a June 2025 public offering expired on September 12, 2026, and that 97% (4 | Sep 14, 2026 |
| AVXL | DEFA14A | bullish | 7/10 | ISS has recommended that Anavex stockholders vote FOR all six of management's director nominees at the September 24, 202 | Sep 14, 2026 |
| BFRI | 8-K | bullish | 7/10 | Biofrontera announced FDA approval of its supplemental New Drug Application for Ameluz (aminolevulinic acid hydrochlorid | Sep 14, 2026 |
| BMRN | 8-K | neutral | 2/10 | BioMarin appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, expanding the board from ten to eleven members | Sep 14, 2026 |
| DFTX | 8-K | bullish | 8/10 | Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT in generalized anx | Sep 14, 2026 |
| EVAX | 6-K | neutral | 3/10 | Evaxion announced it is applying its AI-Immunology platform to autoimmune diseases, testing two novel treatment concepts | Sep 14, 2026 |
| CRDF | 8-K | bullish | 6/10 | Cardiff Oncology and Nerviano Medical Sciences settled their patent inventorship litigation and amended their 2017 exclu | Sep 14, 2026 |
| MDCX | 8-K | neutral | 4/10 | Medicus Pharma Ltd. and Yorkville (YA II PN, LTD.) mutually terminated the Standby Equity Purchase Agreement (SEPA), whi | Sep 14, 2026 |
| HYFT | 6-K | bullish | 6/10 | MindWalk Holdings (HYFT) announced a binding commitment for a $30 million senior unsecured revolving credit facility fro | Sep 14, 2026 |
| NSRX | 6-K | bullish | 7/10 | Nasus Pharma announced FDA clearance of its IND application for NS002, an intranasal epinephrine powder for anaphylaxis, | Sep 14, 2026 |